Crosslinks in Urine - HPLC

Order No.: 48000, for 100 tests
Parameters:
Deoxypyridinoline (DPD), Pyridinoline (PYD)

Hydrolysis resistant internal standard
Easy sample preparation
Accurate and reliable calibration

CE-IVD validated product ready for IVDR within timeframes and transition periods specified by the IVDR 2017/746

Deoxypyridinoline (DPD)

Pyridinoline (PYD)

Clinical relevance

Pyridinoline (PYD) and deoxypyridinoline (DPD) are produced to provide structural stability in the form of crosslinks when collagen fibrils are created. In pathological bone degeneration, the concentrations of PYD and DPD increase in the urine. This is the case with osteoporosis or various bone cancers, for example. Thus PYD and DPD are direct biomarkers for diagnosing post-menopausal osteoporosis and monitoring therapy after intake of drugs. A significant drop in crosslinks in the urine can be observed after just a few months of successful treatment. Furthermore, crosslink concentrations in the urine are subject to ongoing monitoring in patients at greater risk of fracture, so that suitable measures can be taken right away if the levels are already high.

 

Product advantages

  • Hydrolysis-resistant internal standard
  • Easy sample preparation
  • Accurate and reliable calibration

 

This kit allows simple and reliable simultaneous quantification of pyridinoline (PYD) and deoxypyridinoline (DPD) in urine using a simple isocratic HPLC system. Chromatographic separation is performed at an RP column with subsequent fluorescence detection. The use of an acidic hydrolysis-resistant internal standard maximises the precision and reliability of the determination. Interfering fluorophores are removed using solid phase extraction, and then PYD, DPD, and internal standard are eluted in one run.

More Information
Method of Analysis HPLC
Number of Tests 100
Please note The freely available information on this website, in particular on the sample preparation, are not sufficient to work with our products. Please read instructions and warning notices on products and/or instruction manuals.
Lower Limit of Quantitation

Pyridinoline: 15 pmol/ml
Deoxypyridinoline: 15 pmol/ml 

Upper Limit of Quantification

Pyridinoline: up to 3200 pmol/ml
Deoxypyridinoline: up to 1200 pmol/ml

Recovery Pyridinoline: 95.5 % (CV: 1.4 %); Deoxypyridinoline: 93.6 % (CV: 2.0 %)
Intraassay

Pyridinoline: CV = 3.8 %
Deoxypyridinoline: CV = 5.9 %

Interassay

Pyridinoline: CV = 5.1 %
Deoxypyridinoline: CV = 8.9 %

Specimen Spontaneous urine or collected for a period
Sample Preparation
  • Add 50 µl Internal Standard to 250 µl urine and hydrolyse with 250 µl 12 N HCl in screw capped glass tubes over night (12-16 h) at 100 °C.

  • Add 2.5 ml Extraction Buffer, mix briefly.

  • To condition the SPE-columns, apply 2.0 ml Wash Buffer and drain by centrifugation.

  • Pipette entire sample volume to conditioned column, drain by centrifugation at approx. 170 x g, discard the effluent.

  • Pipette to each column 2.5 ml Wash Buffer, drain sharply by centrifugation at approx. 700 x g,  discard the effluents, repeat this step twice.

  • Change the collection tubes.

  • Pipette 1.0 ml Elution Buffer to each column and drain completely by centrifugation at approx. 700 x g, collect each eluate and mix well.

  • Inject 50 µl of each eluate into the HPLC system.

Run Time < 15 min
Injection Volume 50 µl
Flow Rate 1.2 ml/min
Column Temperature ambient (~ 25 °C)
Wavelength

EX 290 nm
EM 395 nm

Gradient isocratic
Additional Info Any isocratic HPLC system with fluorescence detector is suitable.

Parameters Deoxypyridinoline (DPD), Pyridinoline (PYD)
The following components are included in the kit:
The following products are not included in the kit but are required for the application of the method:
General lab equipment (non-CE-IVD products), available from Chromsystems:
As a customer please login or register to gain full access.

Deoxypyridinoline (DPD)

Pyridinoline (PYD)

Clinical relevance

Pyridinoline (PYD) and deoxypyridinoline (DPD) are produced to provide structural stability in the form of crosslinks when collagen fibrils are created. In pathological bone degeneration, the concentrations of PYD and DPD increase in the urine. This is the case with osteoporosis or various bone cancers, for example. Thus PYD and DPD are direct biomarkers for diagnosing post-menopausal osteoporosis and monitoring therapy after intake of drugs. A significant drop in crosslinks in the urine can be observed after just a few months of successful treatment. Furthermore, crosslink concentrations in the urine are subject to ongoing monitoring in patients at greater risk of fracture, so that suitable measures can be taken right away if the levels are already high.

 

Product advantages

  • Hydrolysis-resistant internal standard
  • Easy sample preparation
  • Accurate and reliable calibration

 

This kit allows simple and reliable simultaneous quantification of pyridinoline (PYD) and deoxypyridinoline (DPD) in urine using a simple isocratic HPLC system. Chromatographic separation is performed at an RP column with subsequent fluorescence detection. The use of an acidic hydrolysis-resistant internal standard maximises the precision and reliability of the determination. Interfering fluorophores are removed using solid phase extraction, and then PYD, DPD, and internal standard are eluted in one run.

More Information
Method of Analysis HPLC
Number of Tests 100
Please note The freely available information on this website, in particular on the sample preparation, are not sufficient to work with our products. Please read instructions and warning notices on products and/or instruction manuals.
Lower Limit of Quantitation

Pyridinoline: 15 pmol/ml
Deoxypyridinoline: 15 pmol/ml 

Upper Limit of Quantification

Pyridinoline: up to 3200 pmol/ml
Deoxypyridinoline: up to 1200 pmol/ml

Recovery Pyridinoline: 95.5 % (CV: 1.4 %); Deoxypyridinoline: 93.6 % (CV: 2.0 %)
Intraassay

Pyridinoline: CV = 3.8 %
Deoxypyridinoline: CV = 5.9 %

Interassay

Pyridinoline: CV = 5.1 %
Deoxypyridinoline: CV = 8.9 %

Specimen Spontaneous urine or collected for a period
Sample Preparation
  • Add 50 µl Internal Standard to 250 µl urine and hydrolyse with 250 µl 12 N HCl in screw capped glass tubes over night (12-16 h) at 100 °C.

  • Add 2.5 ml Extraction Buffer, mix briefly.

  • To condition the SPE-columns, apply 2.0 ml Wash Buffer and drain by centrifugation.

  • Pipette entire sample volume to conditioned column, drain by centrifugation at approx. 170 x g, discard the effluent.

  • Pipette to each column 2.5 ml Wash Buffer, drain sharply by centrifugation at approx. 700 x g,  discard the effluents, repeat this step twice.

  • Change the collection tubes.

  • Pipette 1.0 ml Elution Buffer to each column and drain completely by centrifugation at approx. 700 x g, collect each eluate and mix well.

  • Inject 50 µl of each eluate into the HPLC system.

Run Time < 15 min
Injection Volume 50 µl
Flow Rate 1.2 ml/min
Column Temperature ambient (~ 25 °C)
Wavelength

EX 290 nm
EM 395 nm

Gradient isocratic
Additional Info Any isocratic HPLC system with fluorescence detector is suitable.

Parameters Deoxypyridinoline (DPD), Pyridinoline (PYD)
The following components are included in the kit:
The following products are not included in the kit but are required for the application of the method:
General lab equipment (non-CE-IVD products), available from Chromsystems:
As a customer please login or register to gain full access.